INIS
thrombin
100%
proteins
62%
patients
46%
plasma
44%
comparative evaluations
34%
covid-19
31%
women
30%
values
30%
evaluation
30%
anticoagulants
28%
estrogens
28%
performance
28%
standardization
24%
sensitivity
23%
risks
22%
reagents
21%
reviews
21%
testing
21%
antibodies
21%
receptors
20%
laboratories
19%
doses
18%
levels
18%
concentration
18%
heparin
17%
data
16%
steroids
14%
inflammation
13%
peaks
13%
hormones
13%
range
13%
detection
12%
biological markers
12%
hemostatics
11%
in vitro
11%
applications
11%
mutations
11%
wave forms
11%
pregnancy
10%
assessments
10%
capacity
10%
vaccines
10%
screening
9%
failures
9%
therapy
9%
investigations
9%
validation
9%
neutrophils
8%
coronaviruses
8%
thrombosis
8%
Pharmacology, Toxicology and Pharmaceutical Science
Thrombin
49%
Activated Protein C Resistance
19%
Hexadimethrine Bromide
12%
Activated Protein C
12%
Blood Stasis
11%
APC
11%
Contraceptive Agent
11%
Hemostatic Agent
10%
Blood Clotting Disorder
10%
Oral Contraceptive Agent
10%
Venous Thromboembolism
8%
Thromboplastin
8%
Heparin
7%
Estrogen Receptor Positive Breast Cancer
7%
Estetrol
7%
Cytokine
7%
Dexamethasone
7%
Observational Study
7%
Direct Oral Anticoagulant
7%
Tamoxifen
7%
Atrial Fibrillation
7%
Pharmacodynamics
7%
Phospholipid
7%
Infection
7%
SARS Coronavirus
7%
Neutralizing Antibody
7%
Estrogen Receptor
7%
Ultra High Performance Liquid Chromatography
5%
Thrombosis
5%
Keyphrases
Sensitivity Ratio
11%
Resistance Test
9%
Cytokine Response
7%
Polybrene
7%
ST Genesia
7%
Analytical Samples
7%
Performance Stability
7%
Global Coagulation Tests
7%
Estrogen Receptor-positive Breast Cancer
7%
Antigen Test
7%
APC Resistance
7%
COVID-19 Shocks
7%
Critical COVID-19
7%
Regulatory Needs
7%
Unmet Medical Need
7%
Contraceptives
7%
Clinical Investigation
7%
Minimum Interference
7%
Optimal Wavelength
7%
Clot Waveform Analysis
7%
Breast Cancer
7%
Breast Cancer Patients
7%
Activated Protein C
7%
Asundexian
7%
Literature Review Analysis
7%
Omicron Sub-lineages
7%
Estrogen Receptor
6%
Anti-spike
5%
Spike Receptor Binding Domain
5%
Factor V Leiden mutation
5%